---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093893"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:59:09.545486+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Organogenesis Q2 revenue up 11% but net loss $17M on $22.8M impairment and write-downs

## Summary
- Net revenue $130.2M (+11% YoY); Advanced Wound Care $123.2M (+12%), Surgical & Sports Med $7.0M (-3%).
- Net loss $17.0M ($0.13/sh) vs net income $5.3M Q2 2023; included $18.8M impairment and $4.0M software write-down.
- Adjusted EBITDA essentially flat at $15.6M; adjusted net income fell to $0.2M from $6.1M.
- FY2024 revenue guidance reaffirmed $445-$470M; net loss guided $(27)-$(12)M; Adj. EBITDA $16-$35M.
- Cash $90.5M, debt $63.5M; management cites near-term variability in skin substitutes market.

## SEC filing metadata
- accession: 0000950170-24-093893
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000095017024093893/0000950170-24-093893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000095017024093893/orgo-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093893
- JSON: https://secwatch.observer/filing/0000950170-24-093893.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093893.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.